BJDX
Bluejay Diagnostics, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$0.83
−1.94%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.8x
Market Cap
$3.72M
MomentumView details →
1D Return
−1.94%
YTD Return
−68.71%
RSI (14)
34.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.8x
Market Cap
$3.72M
RSI (14)
34.2
MomentumView details →
1D Return
−1.94%
YTD Return
−68.71%
SummaryUpdated Jun 1, 2026
Bluejay Diagnostics, Inc. (NASDAQ:BJDX) is a medical device company founded in 2015 and headquartered in Acton, Massachusetts. The company went public in November 2021 and focuses on developing point-of-care diagnostic solutions for healthcare providers. Bluejay operates in the early-stage medical diagnostics sector, developing innovative testing platforms designed to improve patient care through rapid, accurate diagnostic capabilities at the point of care.
Similar companies
Latest newsMore news →
Bluejay Diagnostics reported its financial results for the quarter ended June 30, 2026, and provided an update on clinical, regulatory and manufacturing progress, including advancement of its Symphony IL-6 test toward regulatory submission and commercialization.22d agoBluejay Diagnostics completed enrollment of 750 patients in the SYMON-II clinical validation study for its Symphony IL-6 sepsis test ahead of schedule.45d agoBluejay Diagnostics, Inc. elected Donald Chase, Neil Dey, Svetlana Dey, Douglas Wurth, and Fred Zeidman as directors, effective June 9, 2026.88d ago